FOS样抗原2蛋白表达在新疆维吾尔族2型糖尿病中的应用

Expression level of FOSL2 protein in Uygur patients with type 2 diabetes mellitus in Xinjiang

摘要:

目的  比较FOS样抗原2（FOSL2）蛋白在新疆维吾尔族2型糖尿病（T2DM）及正常糖代谢（NGT）人群中的表达水平，并分析其表达与临床生化指标的相关性。方法  收取2013年10月-2014年10月新疆喀什地区维吾尔族T2DM及NGT对象各50例，测量并记录其一般临床指标，采集血液标本。生化分析仪测定空腹血糖（FPG）以及总胆固醇（TC）等糖脂代谢指标；全自动电化学发光分析仪及配套试剂测定空腹胰岛素（FINS）水平；高效液相色谱法（HPLC）测定糖化血红蛋白（HbAlc）；酶联免疫吸附法（ELISA）测定FOSL2蛋白表达水平。采用SPSS 19.0统计软件进行数据分析。结果  ①与维吾尔族NGT组比较，T2DM组的体重指数（BMI）[（25.02±3.19）vs（28.36±4.01），P =0.000]、FPG[（5.45±0.69）vs（11.4±4.39），P =0.000]、HbA1c[（6.21±1.30）vs（10.20±2.10），P =0.000]、TC[（3.80±0.87）vs（5.16±0.87），P =0.000]、TG[（1.48±0.85）vs（2.21±1.02），P =0.000]、LDL-C[（2.26±0.83）vs（2.63±0.74），P =0.018]水平较高，而HDL-C[（1.19±0.30）vs（1.03±0.34），P =0.011]及FOSL2蛋白表达水平降低[（41.48±26.32）vs（18.09±9.48），P =0.000]；②与维吾尔族NGT组比较，T2DM组的FINS[（11.61±0.94）vs（16.13±1.61），P =0.017]、稳态胰岛素评价指数（HOMA-IR）[（2.74±0.22）vs（7.81±0.75），P =0.000]水平较高；③维吾尔族T2DM患者血清FOSL2蛋白表达水平与BMI（r =-0.44，P =0.005）、FPG（r =-0.39，P =0.013）、HbAlc（r =-0.34，P =0.044）、TC（r =-0.35，P =0.027）呈负相关。回归分析示BMI（β=-2.17，P =0.032）为FOSL2蛋白表达水平的影响因素。结论  FOSL2蛋白表达水平下调可能参与新疆维吾尔族胰岛素抵抗及T2DM的发生发展，BMI是维吾尔族T2DM的FOSL2蛋白表达水平的重要影响因素。

Abstract:

Objective To compare the expression level of Fos-like antigen 2 (FOSL2) protein in Uygur people with type 2 diabetes mellitus (T2DM) and normal glucose tolerance (NGT) in Xinjiang, and analyze the correlation between FOSL2 expression and clinical and biochemical indicators of those subjects. Methods  Fifty Uygur adults with T2DM (T2DM group) and fifty with NGT (NGT group) were collected as subjects from October 2013 to October 2014 in Kashi area of Xinjiang. The general clinical indicators were measured and recorded, blood samples were collected at the same time. The metabolic markers such as fasting blood glucose (FPG) and total cholesterol (TC) were measured by clinical chemistry analyzer. The level of fasting insulin (FINS) was measured by automatic chemiluminescence analyzer. Glycosylated hemoglobin (HbAlc) was measured by high performance liquid chromatography. The expression level of FOSL2 protein was examined by enzyme-linked immunosorbent assay (ELISA). Data was analyzed by SPSS 19.0. Results Compared with the NGT group, BMI [(25.02 ± 3.19) vs (28.36 ± 4.01), P = 0.000], FPG [(5.45 ± 0.69) vs (11.4 ± 4.39), P = 0.000], HbA1c [(6.21 ± 1.30) vs (10.20 ± 2.10), P = 0.000], TC [(3.80 ± 0.87) vs (5.16 ± 0.87), P = 0.000], TG [(1.48 ± 0.85) vs (2.21 ± 1.02), P = 0.000] and LDL-C [(2.26 ± 0.83) vs (2.63 ± 0.74), P = 0.018] increased; however, HDL-C [(1.19 ± 0.30) vs (1.03 ± 0.34), P = 0.011] and the expression level of FOSL2 protein [(41.48 ± 26.32) vs (18.09 ± 9.48), P = 0.000] decreased in the T2DM group. Compared with the NGT group, FINS [(11.61 ± 0.94) vs (16.13 ± 1.61), P = 0.017], HOMA-IR [(2.74 ± 0.22) vs (7.81 ± 0.75), P = 0.000] increased in the T2DM group. BMI (r = -0.44, P = 0.005), FPG (r = -0.39, P = 0.013), HbAlc (r = -0.34, P = 0.044) and TC (r = -0.35, P = 0.027) were negatively correlated with the serum level of FOSL2 protein in the Uygur patients with T2DM in Xinjiang. BMI (β = -2.17, P = 0.032) was involved in the regression equation which showed that BMI influenced the expression level of FOSL2 protein. Conclusions The lowered expression level of FOSL2 protein may be involved in the occurrence and progression of insulin resistance and T2DM in Uygur in Xinjiang. BMI is an important factor influencing the expression of FOSL2 protein in T2DM patients of Uygur.